$ 124.56
Key Takeaways
Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of RGEN is 182 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
